Neurovascular unit disruption and blood-brain barrier leakage in MCT8 deficiency

Fluids Barriers CNS. 2023 Nov 3;20(1):79. doi: 10.1186/s12987-023-00481-w.

Abstract

Background: The monocarboxylate transporter 8 (MCT8) plays a vital role in maintaining brain thyroid hormone homeostasis. This transmembrane transporter is expressed at the brain barriers, as the blood-brain barrier (BBB), and in neural cells, being the sole known thyroid hormone-specific transporter to date. Inactivating mutations in the MCT8 gene (SLC16A2) cause the Allan-Herndon-Dudley Syndrome (AHDS) or MCT8 deficiency, a rare X-linked disease characterized by delayed neurodevelopment and severe psychomotor disorders. The underlying pathophysiological mechanisms of AHDS remain unclear, and no effective treatments are available for the neurological symptoms of the disease.

Methods: Neurovascular unit ultrastructure was studied by means of transmission electron microscopy. BBB permeability and integrity were evaluated by immunohistochemistry, non-permeable dye infiltration assays and histological staining techniques. Brain blood-vessel density was evaluated by immunofluorescence and magnetic resonance angiography. Finally, angiogenic-related factors expression was evaluated by qRT-PCR. The studies were carried out both in an MCT8 deficient subject and Mct8/Dio2KO mice, an AHDS murine model, and their respective controls.

Results: Ultrastructural analysis of the BBB of Mct8/Dio2KO mice revealed significant alterations in neurovascular unit integrity and increased transcytotic flux. We also found functional alterations in the BBB permeability, as shown by an increased presence of peripheral IgG, Sodium Fluorescein and Evans Blue, along with increased brain microhemorrhages. We also observed alterations in the angiogenic process, with reduced blood vessel density in adult mice brain and altered expression of angiogenesis-related factors during brain development. Similarly, AHDS human brain samples showed increased BBB permeability to IgG and decreased blood vessel density.

Conclusions: These findings identify for the first time neurovascular alterations in the MCT8-deficient brain, including a disruption of the integrity of the BBB and alterations in the neurovascular unit ultrastructure as a new pathophysiological mechanism for AHDS. These results open a new field for potential therapeutic targets for the neurological symptoms of these patients and unveils magnetic resonance angiography as a new non-invasive in vivo technique for evaluating the progression of the disease.

Keywords: Blood–brain barrier; MCT8 deficiency; Neurovascular unit; Rare disease; Thyroid hormone transporters; Thyroid hormones.

MeSH terms

  • Animals
  • Blood-Brain Barrier / metabolism
  • Humans
  • Immunoglobulin G
  • Mental Retardation, X-Linked* / diagnosis
  • Mental Retardation, X-Linked* / genetics
  • Mental Retardation, X-Linked* / pathology
  • Mice
  • Monocarboxylic Acid Transporters / genetics
  • Monocarboxylic Acid Transporters / metabolism
  • Muscle Hypotonia / diagnosis
  • Muscle Hypotonia / genetics
  • Muscle Hypotonia / metabolism
  • Muscular Atrophy / diagnosis
  • Muscular Atrophy / genetics
  • Muscular Atrophy / metabolism
  • Symporters* / genetics
  • Symporters* / metabolism
  • Symporters* / therapeutic use
  • Thyroid Hormones / metabolism
  • Thyroid Hormones / therapeutic use

Substances

  • Immunoglobulin G
  • Monocarboxylic Acid Transporters
  • SLC16A2 protein, human
  • Symporters
  • Thyroid Hormones
  • Slc16a2 protein, mouse

Supplementary concepts

  • Allan-Herndon-Dudley syndrome